Navitus: Specialty Drugs and GLP-1s Continue to Drive Drug Trend
The Navitus 2025 Drug Trend Report found that prescription drug costs for its clients increased 8.4%, reaching $120.08 per member per month, driven primarily by specialty medications and GLP‑1 therapies. Navitus Chief Pharmacy Officer, Sharon Faust, PharmD, MBA, sat down with Managed Healthcare Executive to discuss the primary drivers of drug spend and key cost-containment strategies.
MORE ABOUT Sharon Faust, PharmD, MBA, CSP
Sharon Faust is the Chief Pharmacy Officer at Navitus Health Solutions. She oversees Health Strategies, Provider Services and Lumicera Health Services. She is a licensed pharmacist in Wisconsin and is on the Board of Directors for the National Association of Specialty Pharmacy and the Drug Selection Advisory Committee for CivicaScript®. In 2023, she was awarded the Top 50 Most Influential Leaders in Pharmacy Award presented by the Pharmacy Podcast network.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
CLARITY FOR ACTION
Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download
Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Related blogs
Navigating Healthcare and Improving Outcomes
PBM 101: Demystifying the Complex World of Specialty Drugs
Unless you work in the pharmacy benefit management (PBM) industry, it’s easy to assume that a “specialty drug” is simply a more expensive prescription. In reality, specialty medications sit in a separate category, with different rules and far bigger consequences…
